Our experts reflect on the trends that shaped the European pricing and market access landscape in 20...
Read moreWe discuss the advantages and disadvantages of using international reference pricing for consistent ...
Read moreWe explore the pricing dynamics of biosimilars, which depend on the type of biosimilar, its indicati...
Read moreThe short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...
Read moreIntroduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...
Read moreIntroduction Gene and CAR-T cell therapies are often heralded as the future of healthcare, where gro...
Read moreIntroduction Despite the impact of the COVID-19 pandemic with many resources steered towards managem...
Read moreIntroduction Early Access Programs, also known as special access programs, give patients access to m...
Read moreIntroduction Following Brexit, regulatory oversight in the UK has switched from the European Medicin...
Read moreIntroduction On 1 July 2021, France made changes to its long-standing Authorization for Temporary Us...
Read more